Here's another exciting new headline: Unlikely drug may block breast cancer in high-risk women. But then as you read it, you end up feeling deflated. Why? Because you find out at the end that it will take 10 years before the results of clinical trials will be available. And that it is based on a very small research pool. But here goes. So a drug, denosumab (or Prolia) used to to treat osteoporosis appears to prevent growth of breast cancer in high risk (read BRCA1+) women. This could be a prevention strategy for this group of women. This sounds like fantastic news. "For the study, 33 samples of breast tissue with no BRCA1 mutations and 24 samples of breast tissue with the mutations were analyzed."So its a little tiny group. I am not sure that I am too impressed with the size of this group. And that the results were published based on such a small group. You would think that since the drug is approved already it would be fairly quick to be available for this use but since the clinical trials will take so long to see if cancer growth is prevented it will take ten years to get through trials and then FDA approval, and then finally available. As the article concludes it might be a solution for future generations. I am just a little deflated as I went from high expectations to a long wait.
Source: Caroline's Breast Cancer Blog - Category: Cancer & Oncology Tags: breast cancer cancer prevention cancer risk Source Type: blogs

Related Links:

ConclusionsThis study found no evidence that Family Medicine Groups affected screening rates for these 3 chronic diseases. Limitations in the implementation of the Family Medicine Group policy in its early years may have contributed to this lack of impact. Interprofessional primary care teams may need to include elements other than organizational changes to increase disease prevention efforts.
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
ConclusionOur study provides suggestive evidence for the potential utility of OPG/RANKL ratios in predicting risk of fracture in women treated with AIs for breast cancer. Further validation may be warranted.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
The objective is to provide a sound pathophysiological background along with evidence-based and practical recommendations for physicians managing such women. PMID: 31853818 [PubMed - as supplied by publisher]
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
By HANS DUVEFELT, MD Medical researchers and their groupies – early adopters, thoughtleaders, those easily influenced or whatever you want to call them – never seem to learn that when you try to outsmart Mother Nature or Our Heavenly Father, whichever appeals more to your world view, you usually get your hand slapped. When I was a resident (1981-1984), I got penalized if I didn’t offer postmenopausal women estrogen-progesterone replacement therapy because it seemed obvious that if women with endogenous estrogen didn’t get many strokes or heart attacks and women without estrogen did, all we nee...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Primary Care Hans Duvefelt Source Type: blogs
The 8 cases selected for this presentation include medication-related osteonecrosis of the jaw (MRONJ) treated conservatively: 2 cases of breast cancer metastasis, 3 cases of multiple myeloma, and 3 cases of osteoporosis. Two of them occurred in the implant area and in 1 case, the treatment was concluded with hyperbaric oxygen therapy. In 5 cases, a bisphosphonate was given via intravenous route and 3 cases by oral administration. Only 1 case had a combination of bisphosphonates and monoclonal antibody (denosumab).
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Source Type: research
AbstractPurpose of ReviewThe goal of the review is to assess the appropriateness of menopausal hormone therapy (MHT) for the primary prevention of bone loss in women at elevated risk in the early years after menopause.Recent FindingsEstrogen alone or combined with progestin to protect the uterus from cancer significantly reduces the risk of osteoporosis-related fractures. MHT increases type 1 collagen production and osteoblast survival and maintains the equilibrium between bone resorption and bone formation by modulating osteoblast/osteocyte and T cell regulation of osteoclasts. Estrogens have positive effects on muscle an...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
Spécificités du traitement médicamenteux antihypertenseur chez la femme. Presse Med. 2019 Nov 14;: Authors: Amar J, Angoulvant T, Boivin JM, Amar L, Lantelme P, Blacher J, Plu-Bureau G, Vehier CM Abstract The impact of antihypertensive drugs on blood pressure does not differ according to the sex. There are women-specific conditions or medical conditions encountered more frequently among womens that guide the selection of therapy such as a desire to become pregnant, a pregnancy, a polycystic ovarian syndrome, breast cancer, osteoporosis or migraine. PMID: 31735525 [PubMed - as...
Source: Presse Medicale - Category: General Medicine Authors: Tags: Presse Med Source Type: research
AbstractBackground.Aromatase inhibitors (AIs) used in breast cancer induce loss in bone mineral density (BMD) and are reported to increase fracture risk.Materials and Methods.Using a population‐based BMD registry, we identified women aged at least 40 years initiating AIs for breast cancer with at least 12 months of AI exposure (n = 1,775), women with breast cancer not receiving AIs (n = 1,016), and women from the general population (n = 34,205). Fracture outcomes were assessed to March 31, 2017 (mean, 6.2 years for AI users).Results.At baseline, AI users had higher body mass index (BMI), higher BMD, lower osteoporosis pr...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Breast Cancer, Endocrinology Source Type: research
AbstractPurpose of ReviewThe purpose of this review is to explore the role of monocyte chemoattractant protein-1 (MCP-1 or CCL2) in the processes that underpin bone remodelling, particularly the action of osteoblasts and osteoclasts, and its role in the development and metastasis of cancers that target the bone.Recent FindingsMCP-1 is a key mediator of osteoclastogenesis, being the highest induced gene during intermittent treatment with parathyroid hormone (iPTH), but also regulates catabolic effects of continuous PTH on bone including monocyte and macrophage recruitment, osteoclast formation and bone resorption. In concer...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
Quantification of vertebral bone marrow (VBM) water –fat composition has been proposed as advanced imaging biomarker for osteoporosis. Estrogen deficiency is the primary reason for trabecular bone loss in postm...
Source: BMC Musculoskeletal Disorders - Category: Orthopaedics Authors: Tags: Research article Source Type: research
More News: Blogging | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Orthopaedics | Osteoporosis | Study | Women | Xgeva